Betaleukin in therapy of chronic hepatitis C
https://doi.org/10.22625/2072-6732-2014-6-3-27-33
Abstract
The article presents the problems of modern antiviral therapy of chronic hepatitis C. The effectiveness of combined therapy with pegylated interferon and ribavirin in patients infected with 1st genotype is not more than 50%. Inclusion in the therapy HCV’s protease inhibitors (telaprevir and boceprevir) increases the sustainable virological response in patients with the 1st genotype, but this treatment is more expensive and accompanied by more serious complications. There is a large group of patients in Russia, who can’t have got such treatment because of its high cost. The results of clinical studies in application of betaleukin (recombinant IL-1β) in combined antiviral therapy of chronic hepatitis C also are analyzed.
About the Authors
E. S. Romanova
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
N. I. Kuznetsov
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
G. Yu. Startseva
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Pimenov N.N. Gepatit S v Rossii: jepidemiologicheskaja harakteristika i puti sovershenstvovanija diagnostiki i nadzora/N.N.Pimenov, V.P. Chulanov, S.V. Komarova i dr. // Jepidemiologija i infekcionnye bolezni.- 2012.- № 3.- S.4-10.
2. European Association for the Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection//J Hepatol.- 2011.-V.55,№ 2.- Р. 245-264.
3. Deuffic-Burban S. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France / S. Deuffic- Burban, G. Babany, I. Lonjon-Domanec, et. al.// Hepatology.- 2009.-V.50.- P. 1351-59.
4. Jacobson I.M Treatment options for patients with chronic hepatitis C not responding to antiviral therapy// Clin Gastroenterol Hepatol.- 2009.-V.7.- P 921-30.
5. Manns M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial/ M.P. Manns, J.G. McHutchison, S.C. Gordon, et. al. // Lancet. – 2001.- V. 358 (9286). P.- 958–965.
6. Pawlotsky J. The hepatitis C virus life cycle as a target for new antiviral therapies/ J.Pawlotsky, S. Chevaliez, J. Mchutchison // Gastroenterology.- 2007.- V.- 132.- P.- 1979-1998.
7. Jacobson I.M. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection/ I.M. Jacobson, J.G. McHutchison, G. Dusheiko, et al. // N. Engl. J. Med.- 2011.- V. 364.- P. 2405–2416.
8. Sherman K.E. Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection/ K.E Sherman, S. Flamm, N.Afdhal, et.al.// N. Engl. J. Med.- 2011.-V. 365.- P. 1014–1024.
9. Zeuzem, S. Telaprevir for Retreatment of HCV Infection / S. Zeuzem, P.Andreoni, S.Pol , et.al. // N. Engl. J. Med.- 2011. -V. 364.-P. 2417–2428.
10. Bacon, B. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection / B. Bacon, S. Gordon, E. Lawitz, et.al. // N. Engl. J. Med.- 2011.V.- 364.- P. 1207–1217.
11. Poordad F. Boceprevir for untreated chronic HCV genotype 1 infection/ F.Poordad, J.Jr. McCone, B.R Bacon et.al.//N. Engl. J. Med.- 2011.- V. 364.- P. 1195–1206
12. Cammla C. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C/ C. Cammla, S.Petta, M.Enea et.al. // Hepatology .- 2012.-V. 56. – P. 850-60.
13. Ghany M.G. An update on treatment of genotype1 chronic hepatitis C virus infection: 2011 practice guideline by American Association for the Study of Liver Diseases / M.G. Ghany, D.R. Nelson, D.B. Strader // Hepatology.- 2011.-V. 54. P.- 1433-1444.
14. Moghaddam A. IL28B polymorphism determines treatment response of hepatitis C virus genotype 3 infection. /A. Moghaddam, E.Melum, N.Reinton et.al. //Hepatology.- 2011.- V.53.-P. 746-754.
15. Вирусные гепатиты / К.В. Жданов [и др.] – СПб.: Фолиант, 2011. – 304 с. Virusnye gepatity / K.V. Zhdanov[i dr.] – SPb.: Foliant, 2011. – 304 s.
16. Ketlinskij S.A. Citokiny / S.A. Ketlinskij, A. S. Simbircev–SPb: OOO «Izdatel'stvo FOLIANT», 2008. – 552 s.
17. Lai C.F. Interleukin-1 induces production of granulocyte colony-stimulating factor in human hepatoma cells /C.F. Lai, H. Bauman // Blood.- 1996.- V. 87.-P. 4143-4148.
18. Simbircev A.S. Biologija semejstva interlejkina-1 cheloveka//Immunologija.- 1998. – № 3. – S. 9–17.
19. Simbircev A.S. Interlejkin-1: ot jeksperimenta v kliniku//Medicinskaja immunolo¬gija.- 2001.-T. 3, №3.- S. 431–438.
20. Romanova E.S. Kliniko-immunologicheskoe obosnovanie primenenija Betalejkina v kompleksnoj terapii virusnyh gepatitov V i S:avtoref. dis. … kand. med. nauk./ E.S. Romanova. – SPb.:MAPO, 2000. – 22 s.
21. Kabanova V.I. Kliniko-immunologicheskoe obosnovanie primenenija betalejkina s interferonom α v terapii hronicheskogo gepatita S v replikativnoj faze: avtoref. dis. … kand. med. nauk./ V.I. Kabanova.– SPb.: MAPO, 2005. – 24s.
22. Kuznecov N.I. Rezul’taty ispol’zovanija rekombi¬nantnyh preparatov interlejkina-1 beta i interferona al’fa-2b v terapii bol’nyh hronicheskim virusnym gepati¬tom / N.I. Kuznecov, V.I. Kabanova, V.G. Konusova // Klinicheskie perspektivy gastrojenterologii, gepatologii.- 2006.- № 5.- S.8–14.
23. Lobzin Ju.V. Jeffektivnost’ i bezopasnost’ trojnoj terapii s ispol’zovaniem rekombinantnogo nterlejkina-1β, rekombinantnogo interferona-α i ribavirina u pacientov s hronicheskim gepatitom C, inficirovannyh genotipom 1, s otsutstviem otveta na predshestvujushhee lechenie interferonom i ribavirinom /Ju.V. Lobzin, K.V Zhdanov, A.S. Simbircev i dr. // Zhurnal infektologii.- 2012. – T. 4, №4. – S. 81-89.
24. Jensen, D. Pegylated interferon alfa-2a (40KD) plus ribavirin(RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study.// Ann. Intern. Med.- 2009.- V. 150.- P. 528–540.
25. Zhu H. Interleukin 1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinasepathway / H.Zhu , C.Liu // J. Virology.- 2003.- V. 77.-P. 5493–5498.
26. Duong F.H. Hepatitis C Virus Inhibits Jak-STAT Signaling Through Up-regulation of Protein Phosphatase 2A./F.H.Duong, M. Filipowicz, M.Tripodi //Gastroenterology.- 2004. – V.126, № 1. – P. 263–277.
Review
For citations:
Romanova E.S., Kuznetsov N.I., Startseva G.Yu. Betaleukin in therapy of chronic hepatitis C. Journal Infectology. 2014;6(3):27-33. (In Russ.) https://doi.org/10.22625/2072-6732-2014-6-3-27-33
Views:
743
.png)
.png)
Email this article 